Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian I Rini

Showing results (121-130 of 401) with videos related to

Pageof 41
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2002
Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical resultsBrian I Rini, Todd Zimmerman, Walter M Stadler, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 10, 2002
Flt-3 ligand and sequential FL/interleukin-2 in patients with metastatic renal carcinoma: clinical and biologic activityBrian I Rini, Ajit Paintal, Nicholas J Vogelzang, et al.
Clinical Genitourinary Cancer|February 15, 2008
Prolonged complete responses and near-complete responses to sunitinib in metastatic renal cell carcinomaDaniel Y C Heng, Brian I Rini, Jorge Garcia, et al.
Seminars in Oncology|December 8, 2009
Clinical trial experience with temsirolimus in patients with advanced renal cell carcinomaGary R Hudes, Anna Berkenblit, Jay Feingold, et al.
AJR. American Journal of Roentgenology|May 22, 2010
Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapyAndrew Dennis Smith, Shetal N Shah, Brian I Rini, et al.
Urologic Oncology|September 30, 2011
Utilizing pre-therapy clinical schema and initial CT changes to predict progression-free survival in patients with metastatic renal cell carcinoma on VEGF-targeted therapy: a preliminary analysisAndrew D Smith, Shetal N Shah, Brian I Rini, et al.
Cancer|June 1, 2006
Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapyBrian I Rini, Vivian Weinberg, Lawrence Fong, et al.
Cancer Cell|May 27, 2020
The COVID-19 and Cancer Consortium: A Collaborative Effort to Understand the Effects of COVID-19 on Patients with CancerSamuel M Rubinstein, John A Steinharter, Jeremy Warner, et al.
The Prostate|October 24, 2008
The HLA-A2-restricted PSMA peptide LLHETDSAV is poorly immunogenic in patients with metastatic prostate cancerDavid Knight, Amy C Peterson, Brian I Rini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2007
A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancerEric J Small, N Simon Tchekmedyian, Brian I Rini, et al.
Pageof 41

Showing results (121-130 of 401) with videos related to

Sort By:
Pageof 41
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2002
Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical resultsBrian I Rini, Todd Zimmerman, Walter M Stadler, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 10, 2002
Flt-3 ligand and sequential FL/interleukin-2 in patients with metastatic renal carcinoma: clinical and biologic activityBrian I Rini, Ajit Paintal, Nicholas J Vogelzang, et al.
Clinical Genitourinary Cancer|February 15, 2008
Prolonged complete responses and near-complete responses to sunitinib in metastatic renal cell carcinomaDaniel Y C Heng, Brian I Rini, Jorge Garcia, et al.
Seminars in Oncology|December 8, 2009
Clinical trial experience with temsirolimus in patients with advanced renal cell carcinomaGary R Hudes, Anna Berkenblit, Jay Feingold, et al.
AJR. American Journal of Roentgenology|May 22, 2010
Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapyAndrew Dennis Smith, Shetal N Shah, Brian I Rini, et al.
Urologic Oncology|September 30, 2011
Utilizing pre-therapy clinical schema and initial CT changes to predict progression-free survival in patients with metastatic renal cell carcinoma on VEGF-targeted therapy: a preliminary analysisAndrew D Smith, Shetal N Shah, Brian I Rini, et al.
Cancer|June 1, 2006
Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapyBrian I Rini, Vivian Weinberg, Lawrence Fong, et al.
Cancer Cell|May 27, 2020
The COVID-19 and Cancer Consortium: A Collaborative Effort to Understand the Effects of COVID-19 on Patients with CancerSamuel M Rubinstein, John A Steinharter, Jeremy Warner, et al.
The Prostate|October 24, 2008
The HLA-A2-restricted PSMA peptide LLHETDSAV is poorly immunogenic in patients with metastatic prostate cancerDavid Knight, Amy C Peterson, Brian I Rini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2007
A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancerEric J Small, N Simon Tchekmedyian, Brian I Rini, et al.
Pageof 41